Deficiency of Socs3 leads to brain-targeted experimental autoimmune encephalomyelitis via enhanced neutrophil activation and ROS production

Zhaoqi Yan,1 Wei Yang,1 Luke Parkitny,1 Sara A. Gibson,2 Kevin S. Lee,1 Forrest Collins,1 Jessy S. Deshane,1 Wayne Cheng,4 Amy S. Weinmann,4 Hairong Wei,1 Hongwei Qin,1 and Etty N. Benveniste1

1Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 3Department of Medicine, and 4Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Introduction

Multiple sclerosis (MS) is an autoimmune disease that affects the CNS (1). The disease causes severe demyelination and neuronal loss in both the brain and spinal cord, which leads to neurological dysfunction, including visual loss, limb weakness, ataxia, and impaired cognition (2, 3). Although there are 17 FDA-approved disease-modifying therapies, none is able to stop disease progression (3). The pathobiology of MS is very complex, and both innate and adaptive immunity contribute to disease development and progression (4). Experimental autoimmune encephalomyelitis (EAE) is a widely used mouse model of MS mediated by autoimmune CD4+ T cells and cells of the innate immune system (5). Clinical and histopathological similarities between MS and EAE allow findings obtained from the EAE model to be extrapolated to patients with MS.

Neutrophils are the most abundant cell type in human blood and are the first responders of the immune system when the body encounters foreign antigens or sterile inflammation (6, 7). Neutrophils initiate immune responses by secretion of proinflammatory cytokines/chemokines, degranulation, generation of ROS, formation of neutrophil extracellular traps (NETs), and antigen presentation (6, 8–10). Neutrophils are involved in the pathology of CNS autoimmune diseases, such as MS/EAE and neuromyelitis optica spectrum disorder (NMOSD) (11–15). Neutrophils contribute to EAE disease by secretion of proinflammatory cytokines (16, 17), promoting maturation of antigen-presenting cells, such as dendritic cells and macrophages (18), and disruption of the blood-spinal cord barrier (19). Neutrophil-related chemokines/mediators (G-CSF, CXCL1, CXCL8, ...
CXCL5, and neutrophil elastase) correlate with neurological disability and lesion burden in MS patients (20). Neutrophils from MS patients exhibit a primed, hyperactivated phenotype compared with healthy controls (21). Moreover, several studies indicate that administration of granulocyte colony-stimulating factor (G-CSF), the cytokine that is critical for maturation of neutrophils, leads to MS relapses (22, 23). NMOSD is an autoimmune demyelinating disease distinct from MS, characterized by optic neuritis, astrocytopathy and serum antibodies against Aquaporin-4 (24). Neutrophils are prominent in CNS lesions and cerebrospinal fluid from NMOSD patients (25). Indeed, cerebrospinal fluid from patients with NMOSD induces neutrophil chemotaxis and activation, resulting in astrocyte activation to a proinflammatory phenotype (26). G-CSF also plays a detrimental role in patients with NMOSD (27).

The JAK/STAT signaling pathway plays a critical role in activation and regulation of immune responses (28). Dysregulation of the JAK/STAT pathway is associated with many pathological conditions, including MS (29, 30). We previously demonstrated that inhibition of the JAK/STAT pathway ameliorates disease severity in a number of EAE models (31). STAT3 has been identified as an MS susceptibility gene (32, 33), and hyperactivation of STAT3 is observed in PBMCs from MS patients and correlates with disease progression (34). SOCS are a family of proteins that negatively regulate the JAK/STAT pathway (35). SOCS3 inhibits activation of STAT1 and STAT3, thereby terminating signaling through this pathway (36–38). Reduced SOCS3 expression has been observed in PBMCs from MS patients during relapses, which correlates with enhanced STAT3 activation (39). In NMOSD, clinical benefit has been observed with anti–IL-6R antibody treatment (40). The deleterious role of IL-6 is speculated to be mediated, in part, by IL-6 expansion of Th17 cells (41, 42), which occurs through a STAT3-dependent mechanism (43).

There are different phenotypes of EAE, including classical and atypical. Classical EAE is characterized by ascending paralysis with preferential immune cell infiltration in the spinal cord (5). Atypical EAE is associated with brain inflammation and characterized by ataxia and tremors. Some EAE models display a mixed phenotype of both classical and atypical clinical symptoms. We previously reported that deficiency of Socs3 in myeloid cells (Socs3ΔLysM) leads to a severe, nonresolving, atypical form of EAE (44, 45). Specifically, this brain-targeted, atypical EAE is dependent on preferential neutrophil infiltration in the cerebellum (44). However, the exact mechanism by which neutrophils induce atypical EAE is not clear. Here we demonstrate that neutrophils from Socs3ΔLysM mice produce excessive amounts of ROS, which is critical for the brain-targeted, atypical EAE phenotype. Furthermore, neutrophils lacking Socs3 are hypersensitive to G-CSF priming, which leads to enhanced oxidative burst in response to proinflammatory cytokines, and in vivo, G-CSF depletion significantly reduces atypical EAE disease progression. Overall, our findings demonstrate the importance of Socs3 in controlling the hyperactivation of neutrophils and add to our understanding on the role of neutrophils in MS/EAE.

Results

Socs3ΔLysM mice exhibit brain-targeted EAE with infiltration of hyperactivated neutrophils. Socs3ΔLysM mice with atypical EAE exhibit nonresolving ataxia and tremor, along with preferential cerebellar neutrophil infiltration (44, 45). We assessed demyelination in this model using Black Gold staining, revealing that Socs3ΔLysM mice exhibited cerebellar demyelination at the peak of EAE disease, whereas Socs3ΔΔ mice retained intact myelin structure in the cerebellum (Figure 1A).

Neutrophils have been implicated in both spinal cord–targeted, classical EAE (19, 20, 46, 47) as well as brain-targeted, atypical EAE (44, 48–50), although there is controversy about their exact functions. To address the role of neutrophils in atypical EAE, we first determined levels of surface receptors on cerebellar-infiltrating neutrophils using multicolor flow cytometry analysis (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.126520DS1). The cerebellar-infiltrating neutrophils in Socs3ΔLysM mice exhibited increased surface levels of CD11b and CXCR4 compared with Socs3ΔΔ mice, while surface levels of CD62L and CXCR2 were decreased in Socs3ΔLysM mice compared with Socs3ΔΔ mice (Figure 1, B and C). This altered surface marker expression profile has been associated with a primed neutrophil phenotype (6, 51–53). Primed neutrophils exhibit characteristics that include increased chemotaxis, increased degranulation, and enhanced production of ROS, and these phenotypes are observed in autoimmune conditions (52, 54). Consistent with a phenotype of increased chemotaxis, we found that the numbers of cerebellar neutrophils were significantly increased in Socs3ΔLysM mice at the peak of EAE (Figure 1D). CD63 is a membrane protein associated with intracellular granules. During degranulation, CD63 is expressed on the cell surface as the granule
membrane and cell membrane merge (55). Analysis of surface expression of CD63 revealed that neutrophil degranulation was also increased in Socs3ΔLysM mice at the peak of EAE (Figure 1E).

We next assessed whether ROS production was altered in Socs3ΔLysM mice. To measure total ROS production, neutrophils isolated from the cerebellum were incubated with CM-H2DCFDA, a chemically reduced form of fluorescein used as an ROS indicator in live cells (18, 56). This revealed an increase in the level of ROS+ neutrophils in the cerebellum at the peak of disease in Socs3ΔLysM mice (Figure 1F). ROS production also increased on a per cell basis, as measured by an increase in the MFI of CM-H2DCFDA staining (Figure 1, G and H). To determine whether neutrophils were the primary source of oxidative burst in

Figure 1. Socs3ΔLysM mice exhibit brain-targeted, atypical EAE with infiltration of hyperactivated neutrophils. EAE was induced in both Socs3fl/fl and Socs3ΔLysM mice, and cerebellar tissue was collected at the peak of disease for further analysis. (A) Demyelination was assessed on day 14 and quantified by Black Gold staining (n = 4). Arrows indicate demyelinated regions. (B–J) Immune cells isolated from the cerebellum on days 13–14 using a Percoll gradient were subjected to surface staining. (B) Overlay of cerebellar-infiltrating neutrophils from Socs3fl/fl and Socs3ΔLysM mice stained for CD11b, CXCR4, CD62L, and CXCR2 (n = 7–8). (C) Relative expression of surface markers of cerebellar-infiltrating neutrophils (n = 7–8). (D) Total number of cerebellar-infiltrating neutrophils (n = 7–8). (E) Degranulation was measured by analyzing the percentage of CD63+ neutrophils on days 13–14 (n = 4). (F–I) Before surface staining, isolated neutrophils were incubated with CM-H2DCFDA (1 μM) at 37°C for 30 minutes. (F) Percentage of ROS-producing neutrophils (n = 7–8). (G and H) ROS production by neutrophils measured as the MFI of CM-H2DCFDA staining (n = 7–8). (I) ROS production by different immune cell types from the cerebellum on days 13–14. Neutrophils (CD45+CD11b+Ly6ClowLy6G+), Ly6C+ monocytic cells (Ly6C+ Mo) (CD45+CD11b+Ly6C+Ly6G–), Ly6C– monocytic cells (Ly6C– Mo) (CD45+CD11b+Ly6C–Ly6G–), microglia (CD45loCD11b+), and other leukocytes (CD45+CD11b–). Plot represents 8 individual samples. (J) Superoxide was measured using DHE (n = 4). (K) RNA was isolated from whole cerebellum on day 13, and Hmox1 expression was analyzed by quantitative reverse transcription PCR (qRT-PCR) (n = 4). All error bars represent ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 by 2-tailed Student’s t test. MFI, mean fluorescence intensity; DHE, dihydroethidium.
the cerebellum of Socs3\(^{\Delta \text{LysM}}\) mice, ROS production was measured in neutrophils, monocyctic cells, microglia, and other leukocytes. As shown in Figure 1I, neutrophils produce the highest levels of ROS among these cell populations. Among all the species of free radicals, superoxide produced via NADPH oxidase 2 (NOX2) is considered harmful to endothelial cells and has detrimental roles in CNS inflammation (57–59). We measured superoxide by dihydroethidium (DHE) and consistent with total ROS levels, superoxide was also increased in cerebellar neutrophils from Socs3\(^{\Delta \text{LysM}}\) mice (Figure 1J). To determine oxidative stress in Socs3\(^{\Delta \text{LysM}}\) mice, we measured the expression of Hmox1, a gene induced by ROS (60) in whole cerebellar tissue. Hmox1 mRNA expression was increased at the peak of EAE in Socs3\(^{\Delta \text{LysM}}\) mice compared with Socs3\(^{\text{fl/fl}}\) mice (Figure 1K), indicating an enhanced oxidative stress. Together, these results demonstrate that brain-targeted, atypical EAE pathology in Socs3\(^{\Delta \text{LysM}}\) mice is correlated with a primed neutrophil phenotype and enhanced ROS production.

**Figure 2. ROS plays an important role in the pathology of atypical EAE.** EAE was induced in Socs3\(^{\Delta \text{LysM}}\) mice. Beginning on day 7, ROS scavenger cocktail (FeTPPS 20 mg/kg, PBN 50 mg/kg, and EUK-134 15 mg/kg) was administered i.p. twice per day for 5 days. (A) Atypical EAE score of mice treated with ROS scavenger cocktail (n = 14) or vehicle control (n = 14). Mice that did not develop EAE (classical or atypical) were excluded. (B) Demyelination was assessed on day 14 and quantified by Black Gold staining (n = 3). Arrows indicate demyelinated regions. (C) On days 13 to 14, immune cells from the cerebellum were isolated by Percoll gradient, and the frequencies of microglia (CD45\(^{\text{lo}}\)CD11b\(^{+}\)), neutrophils (CD45\(^{+}\)CD11b\(^{+}\)Ly6C\(^{-}\)Ly6G\(^{+}\)), Ly6C\(^{+}\) monocytic cells (CD45\(^{+}\)CD11b\(^{+}\)Ly6C\(^{-}\)Ly6G\(^{-}\)), Ly6C\(^{-}\) monocytic cells (CD45\(^{+}\)CD11b\(^{+}\)Ly6C\(^{-}\)Ly6G\(^{-}\)), and CD3\(^{+}\) T cells (CD45\(^{+}\)CD11b\(^{-}\)CD3\(^{+}\)) were determined (n = 6). (D) RNA was isolated from whole cerebellum on day 13, and Hmox1 expression was analyzed by qRT-PCR (n = 5). All error bars represent ± SEM. *P < 0.05, and **P < 0.01 by Mann-Whitney rank-sum test (A) or 2-tailed Student’s t test (B–D).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Overall Incidence</th>
<th>Classical(^a)</th>
<th>Atypical(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle control</td>
<td>14/14 (100%)</td>
<td>7/14 (50.0%)</td>
<td>13/14 (92.9%)</td>
</tr>
<tr>
<td>ROS scavenger</td>
<td>14/17 (82.4%)</td>
<td>12/17 (70.5%)</td>
<td>8/17 (47.1%)</td>
</tr>
</tbody>
</table>

\(^a\)Incidence was calculated from all mice. \(^{\chi^2}\)P < 0.01 with \(\chi^2\) test between vehicle control and ROS scavenger groups.
of ROS scavengers to Socs3Δlysm mice 7 days after immunization (56). Administration of ROS scavengers significantly delayed the time of onset and reduced the severity of brain-targeted EAE (Figure 2A). The incidence of brain-targeted EAE was also reduced (92.9% to 47.1%) (Table 1). Administration of ROS scavengers also prevented demyelination in the cerebellum (Figure 2B).

To better understand the underlying mechanism associated with the beneficial effect of ROS scavengers in atypical EAE, we assessed immune cell infiltration in mice treated with the ROS scavenger cocktail. On days 13 to 14, we observed a significant reduction in neutrophils, monocytes, and CD3+ T cells infiltrating the cerebellum in mice treated with ROS scavengers; however, the frequency of microglia was comparable between vehicle control and ROS scavenger treatment (Figure 2C). Hmox1 mRNA expression was significantly reduced in the cerebellar tissues from mice treated with ROS scavengers, indicating an overall reduction of oxidative stress (Figure 2D). To exclude the possibility that treatment with the ROS scavenger cocktail suppresses atypical EAE by affecting T cell priming, we determined the frequency of myelin oligodendrocyte glycoprotein–specific (MOG-specific) T cells after treatment. The frequency of MOG-specific T cells, determined by cytokine production upon either MOG stimulation (Supplemental Figure 2A) or MOG38–49 tetramer staining (Supplemental Figure 2, C and D), were comparable between ROS scavenger treatment and vehicle control. The percentage of regulatory T cells after ROS scavenger treatment was also not changed (Supplemental Figure 2B).

Socs3Δlysm mice can exhibit classical EAE in addition to the predominant atypical EAE phenotype. There was not a significant change in the incidence or severity of classical EAE upon ROS scavenger treatment (Table 1 and Supplemental Figure 2E), indicating that the impact of ROS scavengers was specific to brain-targeted EAE. Collectively, these results demonstrate that ROS plays a critical role in the development of brain-targeted, atypical EAE but not in classical, spinal cord–targeted EAE.

G-CSF treatment promotes a primed phenotype in Socs3-deficient neutrophils via JAK1/STAT3. We next explored the mechanism underlying the primed neutrophil phenotype. SOCS3 negatively regulates STAT3 signaling and is induced upon activation of the JAK/STAT pathway (61). Therefore, we first determined which cytokines induce Socs3 expression in neutrophils. Activation of STAT3 by G-CSF in neutrophils has been well documented (37, 62–64); however, the literature is inconclusive about whether other cytokines, such as IL-6 and IL-23, can activate neutrophils via STAT3 (65, 66). We found that G-CSF treatment induced strong Socs3 expression 2 hours after stimulation and that this response was significantly higher than that induced by other cytokines, such as IL-6 and IL-23 (Figure 3A). In addition, G-CSF treatment led to enhanced STAT3 activation in Socs3-deficient neutrophils, in comparison to Socs3+/− neutrophils (Figure 3, B and C). This difference was not observed in response to IL-6 (Figure 3, B and C) or IL-23 (Supplemental Figure 3, A and B). We previously reported that loss of Socs3 leads to persistent STAT3 activation in response to IFN-γ stimulation in bone marrow–derived macrophages (36). However, in neutrophils, treatment with IFN-γ induced only moderate expression of Socs3 compared with treatment with G-CSF (Figure 3A), and IFN-γ treatment did not lead to enhanced STAT3 activation in Socs3-deficient neutrophils in vitro (Supplemental Figure 3, C and D).

Upon G-CSF stimulation, Socs3-deficient neutrophils exhibited a primed phenotype in vitro, evident as increased surface expression of CD11b and CXCR4 and decreased surface expression of CD62L and CXCR2 relative to Socs3+/− neutrophils (Figure 3, D and E). In contrast, this difference for CD11b or CD62L was not observed upon stimulation with other cytokines, including IFN-γ, IL-17A/F, IL-6, and sIL-6R, IL-23, or IL-6 and IL-23 (Supplemental Figure 3E). We next asked whether the primed phenotype was due to activation of the JAK/STAT pathway. Pretreatment of Socs3-deficient neutrophils with AZD1480, a JAK1/2 inhibitor, or PF8041, a JAK1 inhibitor, impaired G-CSF–induced neutrophil priming (Figure 3F). These results indicate that G-CSF treatment activates the JAK1/STAT3 pathway to elicit a primed phenotype in Socs3-deficient neutrophils in vitro.

G-CSF induces a unique gene expression profile in Socs3-deficient neutrophils. We next determined whether G-CSF stimulation differentially affects gene expression in Socs3-deficient neutrophils. RNA-Seq analysis was performed on Socs3+/− or Socs3-deficient neutrophils that were either unstimulated or stimulated with G-CSF. G-CSF stimulated affected the expression of a large number of genes in both Socs3+/− and Socs3-deficient neutrophils, with more than 2,000 genes significantly upregulated or downregulated after stimulation (Figure 4A). Moreover, a total of 873 genes were upregulated, and 939 genes downregulated, specifically in Socs3-deficient neutrophils compared with Socs3+/− neutrophils (Figure 4B).

A gene set enrichment analysis (GSEA) revealed that a number of signaling pathways related to neutrophil activation were enhanced in Socs3-deficient neutrophils as compared with Socs3+/− neutrophils.
upon G-CSF stimulation (Figure 4C). Upregulated pathways included the NF-κB pathway, which is related to neutrophil activation and chemotaxis in response to TNF-α and TLR ligands (67), and the STAT5 pathway, which is critical for neutrophils to respond to GM-CSF (68). Not surprisingly, STAT3 signaling was also upregulated in Socs3-deficient neutrophils upon G-CSF stimulation compared with Socs3fl/fl neutrophils. G-CSF mobilizes neutrophils by promoting chemotaxis, and our RNA-Seq data indicate that neutrophil migration–related genes were increased in Socs3-deficient neutrophils treated with G-CSF (Figure 4, C and D). Additionally, by qRT-PCR analysis, we confirmed that chemokines that promote neutrophil migration, including Ccl4, Cxcl2, and Cxcl3, were also enhanced in Socs3-deficient neutrophils compared with Socs3fl/fl neutrophils (Figure 4E). The RNA-Seq analysis also indicated that expression of genes related to the secretory vesicle trafficking pathway were increased in Socs3-deficient neutrophils, consistent with an increased potential for degranulation (Figure 4, C and D). In contrast, many of the downregulated pathways in Socs3-deficient neutrophils were associated with neutrophil resolution, including IFN-α responses (Figure 4C). DNA replication– and protein translation–related pathways were also reduced in Socs3-deficient neutrophils, indicating a maturation stage (Figure 4C).
To further determine whether G-CSF stimulated Socs3-deficient neutrophils are more activated compared with Socs3fl/fl neutrophils, we performed enrichment analysis using previously published RNA-Seq gene sets that contain genes expressed by activated neutrophils (stimulated with live bacteria, LPS, or TNF-α) (69, 70, 51). Genes that were increased by such activated neutrophils overlapped extensively with genes that were significantly upregulated in Socs3-deficient neutrophils upon G-CSF stimulation (Supplemental Figure 4). In addition, genes that were reduced after stimulation from the published data overlapped extensively with downregulated genes in Socs3-deficient neutrophils upon G-CSF stimulation (Supplemental Figure 4). Overall, the results from the RNA-Seq analysis indicate that upon G-CSF stimulation, Socs3-deficient neutrophils upregulate neutrophil activation genes and downregulate neutrophil resolution genes.

Figure 4. G-CSF induces a unique gene expression profile in Socs3-deficient neutrophils. Bone marrow neutrophils isolated from Socs3fl/fl and Socs3ΔLysM mice were stimulated with G-CSF (10 ng/ml) for 8 hours, followed by mRNA extraction and RNA-Seq (n = 3). (A) Heatmap of differentially expressed genes (DEGs) among the 4 groups. (B) Venn diagram depicting DEGs between Socs3fl/fl and Socs3-deficient neutrophils in response to G-CSF. (C) DEGs between Socs3-deficient neutrophils and Socs3fl/fl neutrophils upon G-CSF treatment were ranked based on the adjusted P value and log2 fold change. GSEA illustrating upregulated and downregulated pathways in Socs3-deficient neutrophils in response to G-CSF. (D) Upregulated genes from selected pathways. (E) Bone marrow neutrophils isolated from Socs3fl/fl and Socs3ΔLysM mice were stimulated with G-CSF (10 ng/ml) for 8 hours, followed by mRNA extraction and qRT-PCR assay to determine mRNA expression of the indicated chemokines (n = 3–6). All error bars represent ± SEM. **P < 0.01 by 2-tailed Student’s t test.
Socs3-deficient neutrophils are functionally hyperactivated in vitro upon G-CSF priming. Based on the results in Figure 3 and the RNA-Seq data in Figure 4, we hypothesized that Socs3-deficient neutrophils are more sensitive to priming by G-CSF. To test this hypothesis, we first assessed ROS production by neutrophils using a luminol-based assay. For this assay, bone marrow neutrophils were pre-incubated with G-CSF overnight, followed by stimulation with PMA. In contrast with the expectation of our hypothesis, the data indicated that ROS production was comparable between Socs3<sup>fl/fl</sup> and Socs3-deficient neutrophils (Figure 5A).

The RNA-Seq results indicated the possibility that the NF-κB and STAT5 pathways were activated upon G-CSF priming of Socs3-deficient neutrophils (Figure 4C). Therefore, we next tested whether Socs3-deficient neutrophils were more sensitive to cytokines using the NF-κB and STAT5 pathways. TNF-α and GM-CSF are proinflammatory cytokines produced by T cells and myeloid cells in MS/EAE, and neutrophils are responsive to both cytokines (67, 68). Additionally, TNF-α- and GM-CSF–mediated induction of ROS plays a detrimental role during neuroinflammation by disrupting the blood-brain barrier (71, 72). To test the role of these cytokines in ROS induction, we treated neutrophils with TNF-α (Figure 5B) or GM-CSF (Figure 5C) after priming with G-CSF overnight. In the presence of PMA, both cytokines induced higher production of ROS in Socs3-deficient neutrophils compared with Socs3<sup>fl/fl</sup> neutrophils. The G-CSF–primed, Socs3-deficient neutrophils also showed increased degranulation upon LPS stimulation compared with Socs3<sup>fl/fl</sup> neutrophils (Figure 5D). Together, these results indicate that Socs3-deficient neutrophils become hyperactivated in vitro upon G-CSF priming.

G-CSF neutralization ameliorates brain-targeted EAE by preventing neutrophil infiltration and hyperactivation. Our results indicate that G-CSF leads to a primed phenotype in Socs3-deficient neutrophils in vitro and that this phenotype correlates with the incidence of brain-targeted EAE. Therefore, we next examined whether depleting G-CSF is beneficial for brain-targeted EAE. We first examined the levels of G-CSF during EAE, which revealed that G-CSF levels were lower in the plasma of Socs3<sup>ΔLysM</sup> mice compared with Socs3<sup>fl/fl</sup> mice before onset of EAE and were comparable throughout the onset stage and peak of EAE (Supplemental Figure 5A). The levels of G-CSF in the cerebellum were comparable between Socs3<sup>ΔLysM</sup> mice and Socs3<sup>fl/fl</sup> mice (Supplemental Figure 5B). Next, we determined whether G-CSF depletion affected the development or phenotype of EAE. In previous studies, we found that neutrophils migrated into the spleen and lymph nodes throughout the course of EAE in both Socs3<sup>fl/fl</sup> and Socs3<sup>ΔLysM</sup> mice (data not shown). To avoid affecting the possible influence of neutrophils at the
T cell priming stage, anti–G-CSF antibody (Ab) was administered to mice beginning on day 7 after immunization. Administrating neutralizing Ab against G-CSF significantly reduced the levels of G-CSF in plasma (Figure 6A). Depletion of G-CSF significantly reduced the severity (Figure 6B) and incidence (Table 2) of brain-targeted EAE and reduced cerebellar demyelination (Figure 6C). A flow cytometry analysis indicated that G-CSF depletion significantly reduced the frequencies of infiltrating neutrophils and monocytic cells at the peak of EAE, while the frequencies of microglia and infiltrating CD3+ T cells were unchanged (Figure 6D).

The reduced cerebellar infiltration (Figure 6D) correlated with a significant reduction in the frequency of neutrophils and monocytes that were present in the blood after G-CSF depletion (Supplemental Figure 6A and B). In contrast, the frequency of CD3+ T cells present in the blood were not altered (Supplemental Figure 6B). Furthermore, the reduction of neutrophils in the blood did not affect neutrophil frequency in the spleen (Supplemental Figure 6C), suggesting a preferential reduction of CNS infiltration. Consistent with the significant reduction of infiltrating neutrophils in the cerebellum, the overall levels of oxidative stress were decreased, indicated by the reduction of ROS-producing neutrophils in the cerebellum (Figure 6E) and significantly reduced Hmox1 mRNA expression in the cerebellar tissues (Figure 6F). Neutrophil degranulation was also reduced in the cerebellum (Figure 6G). Interestingly, we did not observe a significant change in the incidence of classical EAE (Table 2) or disease severity (Supplemental Figure 7A). G-CSF neutralization did reduce infiltration of neutrophils in the spinal cord, whereas the frequency of microglia, monocytic cells, and CD3+ T cells was not affected (Supplemental Figure 7B). However, the change in neutrophil infiltration did not affect disease incidence or severity. Collectively, these results indicate that G-CSF neutralization ameliorates brain-targeted EAE.

Figure 6. G-CSF neutralization suppresses brain-targeted, atypical EAE. EAE was induced in Socs3ΔLysM mice, and from day 7, anti–G-CSF Ab (20 μg/mouse) or isotype control Ab (20 μg/mouse) was administered i.p. every other day until day 13. (A) On day 12, plasma samples were collected and G-CSF levels determined by ELISA (n = 3). (B) Atypical EAE scoring of mice treated with anti–G-CSF Ab (n = 11) or isotype control Ab (n = 14). Mice that did not develop EAE (classical or atypical) were excluded. (C) Demyelination was assessed and quantified by Black Gold staining (n = 5). Arrows indicate demyelinated regions. (D, E, and G) Immune cells were isolated from the cerebellum 14 days after immunization (n = 5–8). (D) Frequencies of microglia (CD45loCD11b+), neutrophils (CD45+CD11b+Ly6C+Ly6G+), Ly6C+ monocytic cells (CD45+CD11b+Ly6C+Ly6G+), Ly6C– monocytic cells (CD45+CD11b+Ly6C–Ly6G–), and CD3+ T cells (CD45+CD11b+CD3+) from the cerebella of mice treated with isotype Ab and anti–G-CSF Ab were determined. (E) Total numbers of ROS-producing neutrophils in the cerebella from mice treated with isotype Ab and anti–G-CSF Ab. (F) RNA was isolated from whole cerebellum, and Hmox1 expression was analyzed by qRT-PCR (n = 4). (G) Degranulation of cerebellar-infiltrating neutrophils from mice treated with isotype Ab or anti–G-CSF Ab was determined by surface expression of CD63. All error bars represent ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001, and ns, not significant, by Mann-Whitney rank-sum test (B) or 2-tailed Student’s t test (A and C–G).
Discussion

We and others have demonstrated that brain-targeted, atypical EAE is predominantly a neutrophil-driven disease (11, 13, 44, 48, 49, 73, 74). Previously, we reported that neutrophils increase production of proinflammatory cytokines, chemokines, and nitric oxide during onset of atypical EAE in Soc3ΔLysM mice (44).

In the present study, we have elucidated the cellular mechanisms by which neutrophils induce pathological changes in the cerebellum of Soc3ΔLysM mice. We demonstrated that neutrophils from the cerebellum of Soc3ΔLysM mice exhibit a hyperactivated phenotype and increase ROS production, which contributes to the development of atypical EAE. Mechanistically, we found that neutrophil hyperactivation is mediated by enhanced G-CSF signaling through the JAK/STAT pathway in Soc3-deficient neutrophils. Consistent with these results, we demonstrated that G-CSF neutralization has beneficial effects in brain-targeted, atypical EAE. These findings contribute to our understanding of the pathobiology of brain-targeted EAE and document the detrimental role of neutrophils in autoimmune neuroinflammation.

Recent studies suggest that neutrophils are quite heterogeneous and comprise different subsets with distinct functions (6, 75, 76). Zhang et al. reported a unique subset of “aged” neutrophils characterized by high expression of CXCR4 and low expression of CD62L (51). These aged neutrophils represented an overly activated subset of neutrophils that were associated with increased proinflammatory activity and enhanced ROS production. Hawkins et al. reported that in a B cell–dependent, classical EAE model, CNS-infiltrating neutrophils specifically expressed the adhesion molecule ICAM1 (46). These ICAM1+ neutrophils exhibited increased surface expression of CD11b and CD45, formed synapses with T cells and B cells, and mediated inflammatory responses in vivo. These findings suggest that expression of specific neutrophil surface markers could be associated with distinct functions. In the current study, Soc3-deficient, hyperactivated neutrophils exhibited alterations in surface marker expression (elevated CD11b and CXCR4, decreased CD62L and CXCR2), enhanced ROS production, and increased degranulation both in vivo (Figure 1) and in vitro (Figure 3 and Figure 5). These results are consistent with clinical evidence showing that neutrophils from MS patients are characterized by increased TLR2 expression, elevated degranulation, resistance to apoptosis, and enhanced NET and ROS production, indicative of a hyperactivated status (21, 25).

The role of neutrophils in MS and EAE is complex. A number of studies, including from our group, indicate that neutrophils have detrimental functions in EAE (20, 44, 46–49, 77). Neutrophil depletion significantly reduces the incidence and severity of atypical EAE (44). Furthermore, mice lacking G-CSF signaling are resistant to classical EAE, and neutrophil-related chemokine levels correlate with MS lesion burden (20). In addition, overexpression of CXCL1 in the CNS increased neutrophil infiltration and exacerbated demyelination in 2 mouse models of MS, and neutrophil ablation reduced the severity of demyelination, demonstrating a pathogenic role for neutrophils (47, 77). However, a recent study showed polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) restrain accumulation of GM-CSF–producing B cells in the CNS, exerting a protective effect in classical EAE (78). Depletion of PMN-MDSCs after the onset of EAE led to activation of B cells in the CNS, subsequent microglial activation, and lack of recovery from the clinical signs of EAE. In addition, the number of neutrophils negatively correlates with that of B cells in the cerebrospinal fluid of MS patients (78). G-CSF administration at the onset of clinical symptoms reduces EAE severity in SJL/J mice by inhibiting recruitment of T cells to the CNS and suppressing TNF-α production (79). G-CSF administration on day 12 of classical EAE led to expansion of Ly6G+ neutrophils and faster recovery from clinical symptoms than that of control-treated mice (78). In contrast, studies that show a detrimental role for neutrophils, including our findings, typically used models that impaired neutrophil function throughout the course of EAE or starting before the pre-onset phase (20, 44, 48). Furthermore, there is complexity with respect to neutrophils and G-CSF, depending on the phenotype of EAE. Our findings are consistent with Pierson

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Overall Incidence</th>
<th>Classical†</th>
<th>Atypical†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isotype Ab</td>
<td>14/14 (100%)</td>
<td>8/14 (57.1%)</td>
<td>14/14 (100%)</td>
</tr>
<tr>
<td>Anti–G-CSF Ab</td>
<td>11/14 (78.6%)</td>
<td>7/14 (50.0%)</td>
<td>5/14 (35.7%)</td>
</tr>
</tbody>
</table>

†Incidence was calculated from all mice. *P < 0.01 with χ² test between anti–G-CSF Ab and isotype Ab groups.
and Goverman (49), who demonstrated that neutrophils are not necessary for classical EAE. Regarding the role of G-CSF, Rumble et al. (20) demonstrated that mice lacking G-CSF signaling are resistant to classical EAE, using mice with global G-CSFR deletion. In our model, anti–G-CSF Ab was administered on day 7 after immunization and suppressed the brain-targeted, atypical EAE phenotype while not influencing classical EAE. These differences may reflect the timing at which G-CSF signaling is interrupted. Collectively, these findings indicate that the biological functions of neutrophils in EAE are timing, context, and model dependent, with both beneficial and detrimental behaviors (11–13, 15).

Our RNA-Seq analysis identified numerous genes that are differentially expressed in Socs3-deficient neutrophils in response to G-CSF, compared with Socs3ΔLysM mice. Although some of these genes are likely direct targets of STAT3 based on GSEA, the majority are not. GSEA results implicate the NF-κB pathway as the most affected signaling pathway, with more than 150 NF-κB target genes upregulated in Socs3-deficient neutrophils in response to G-CSF compared with Socs3ΔLysM mice. Previous studies have suggested that Socs3 negatively regulates the NF-κB pathway in macrophages (80), and our data suggest that Socs3 may also negatively regulate the NF-κB pathway in neutrophils. The RNA-Seq data also demonstrate that the STAT5 pathway, which GM-CSF activates, is enhanced in Socs3-deficient neutrophils after an 8-hour stimulation with G-CSF. G-CSF priming also rendered Socs3-deficient neutrophils more sensitive to GM-CSF treatment for ROS production. GM-CSF is an important cytokine implicated in EAE/MS (49, 72, 81–83). Our findings demonstrate that G-CSF priming of Socs3-deficient neutrophils, leading to hyperactivation of STAT3, render these cells more sensitive to GM-CSF stimulation. This may contribute, in part, to their detrimental functions. Another interesting finding from our RNA-Seq results is that neutrophils undergo metabolic changes in response to G-CSF, specifically increased glycolysis and reduced oxidative phosphorylation. Genes related to mTOR signaling and hypoxia were also upregulated after G-CSF treatment. Although the literature exploring the relationship between metabolism and neutrophil function is limited, activation of mTOR complex 1 and hypoxia-inducible factor–1α have been shown to correlate with neutrophil activation and increased potential to form NETS (84–86). Previous studies have also demonstrated that Socs3-deficient neutrophils exhibit reduced apoptosis, consistent with our RNA-Seq results showing upregulation of antiapoptotic pathways (37, 38). Overall, our RNA-Seq analysis provides some potential downstream signaling pathways that may be involved in the hyperactivation of Socs3-deficient neutrophils and that will be characterized in the future.

Neutrophils are critically involved in the pathophysiology of numerous CNS diseases, including MS, NMOSD, Alzheimer’s disease, and cerebral ischemia (15, 25, 87–89). The findings from our study may have relevance to NMOSD in addition to MS, given the well-documented presence of neutrophils in CNS lesions and cerebrospinal fluid and findings that neutrophils contribute to astrocyte dysfunction and inflammation in NMOSD animal models (25, 26). Furthermore, neutrophils from patients with NMOSD exhibit some characteristics of activated neutrophils, including increased expression of TLR2 and N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptors (25). Thus, the Socs3ΔLysM model with hyperactivated neutrophils may be of value in further studies of NMOSD pathophysiology. Finally, the composition of the gut microbiome has profound effects on MS and NMOSD pathogenesis (90–92). A role for the gut microbiome in regulating a disease-promoting, primed neutrophil phenotype has recently been described (51). It will be of interest to examine how modulation of the microbiota in Socs3ΔLysM mice may affect neutrophil function and subsequent neuroinflammatory responses in the CNS.

Methods

Mice. C57BL/6 mice were bred in an animal facility at the University of Alabama at Birmingham (UAB). Transgenic mice with the Socs3 locus flanked with flox sequences (Socs3ΔLysM; ref. 93) were the gift of Warren Alexander (Walter and Eliza Hall Institute of Medical Research, Victoria, Australia) and were bred at UAB. Socs3–conditional knockout (Socs3ΔLysMΔ) mice were generated by serial breeding of Socs3ΔLysM mice with mice expressing Cre recombinase under the control of the LysM promoter (45).

EAE induction and assessment. EAE was induced in Socs3ΔLysM mice and Socs3ΔLysMΔ mice by s.c. injection of MOG35–55 emulsified in CFA (Hooke Laboratories, EK-2110), along with i.p. injection of 100 ng pertussis toxin (Hooke Laboratories, EK-2110) on day 0 and day 1, as previously described (44, 45, 94). Mice experience a classical, atypical, or mixed phenotype after EAE induction. Classical EAE was scored as follows: 0, no disease; 1, decreased tail tone; 2, hind limb weakness or partial paralysis; 3, complete hind limb paralysis; 4, front and hind limb paralysis; and 5, moribund state. Assessment of atypical EAE was as follows: 0, no disease; 1, hunched appearance, slight head tilt; 2, ataxia, scruffy coat; 3, severe head tilt, slight axial rotation, staggered walking;
ute. CD45+CD11b+Ly6G+ neutrophils were isolated by flow cytometry and used for qRT-PCR assays. For mice as previously described (36, 44). Red blood cells were lysed by incubation in ACK lysis buffer for 1 min-

μi.p. injection twice a day for 5 to 6 days (56). For G-CSF depletion, 20 mg/kg of anti–G-CSF Ab (R&D Systems, MAB414) or isotype control rat IgG1 Ab (R&D Systems, MAB005) was administered per mouse every other day by i.p. injection from days 7 to 12 after EAE induction (95). Mice were sacrificed on days 13–14 at the peak of EAE development for histology or flow cytometry analysis.

Assessment of demyelination. At the peak of EAE, mice were anesthetized and intracardially perfused with PBS, followed by 4% paraformaldehyde. The cerebellum was fixed with 4% PFA at 4°C overnight and then dehydrated with 30% sucrose. Cryoprotected brains were embedded in OCT compound (Thermo Fisher Scientific) and cryosectioned to produce 40-μm slices in the sagittal plane from the center. Sections were stained using the Black Gold II Myelin Staining Kit (MilliporeSigma, AG105) (96). Images of stained sections were acquired with Keyence Microscope BZ-X800. Total arbor vitae (white matter) area and the myelinated area (area of Black Gold staining) of the cerebellum were measured using the Hybrid Cell Count module provided by Keyence Microscope. The Percentage of Myelinated Area module was defined as myelinated area divided by total arbor vitae (white matter) area.

Abs, cytokines, and inhibitors. For flow cytometry–related experiments, Abs directed against murine CD11b (M1/70), CD45 (30-F11), Ly6C (HK1.4), Ly6G (1A8), CXCR2 (SA044G4), CD62L (MEL-14), IFN-γ (NVG-2), CD3 (17A2), CD4 (GK1.5), CD8 (53-6.7), CD44 (IM7), IFN-γ (XMG1.2), and IL-17A (TC11-18H10.1) were from BioLegend. Abs against GM-CSF (MP1-22E9) and Foxp3 (FJK-16S) were from eBioscience. Tetramer Ab against MOG38–49 (GWYRSPFSRVVH) was a gift from Laurie Harrington (UAB). Abs against CXCR4 (2B11) were purchased from BD Bioscience, and Ab directed against p-STAT3 (Tyr705) was purchased from Cell Signaling Technology. The LIVE/DEAD Fixable Aqua Stain kit was from Thermo Fisher Scientific (L34957). Murine IL-6, IFN-γ, G-CSF, sIL-6R, IL-23, TNF-α, and GM-CSF were purchased from BioLegend. Neutralizing anti–G-CSF Ab was from R&D Systems. AZD1480, a JAK1/2 inhibitor, was a gift from AstraZeneca R&D and dissolved in DMSO as previously described (31). PF8041, a JAK1 inhibitor, was provided by Pfizer and dissolved in DMSO.

Neutrophil isolation. Bone marrow cells were isolated from the femurs of C57BL/6 Socs3fl/fl or Socs3fl/+ mice as previously described (36, 44). Red blood cells were lysed by incubation in ACK lysis buffer for 1 minute. CD45−CD11b+Ly6G− neutrophils were isolated by flow cytometry and used for qRT-PCR assays. For functional assays, neutrophils were isolated using the negative selection procedure from the EasySep Mouse Neutrophil Enrichment Kit (Stemcell Biotechnologies).

Quantitative real-time PCR and RNA-Seq. Neutrophils isolated by flow cytometry were stimulated as indicated. Total RNA was purified from cells using Trizol reagent extraction, and 500 ng to 2 μg of RNA was sent to GENEWIZ for RNA-Seq and bioinformatics analysis. RNA-Seq results were submitted to the National Center for Biotechnology Information Gene Expression Omnibus database for archiving under accession number GSE122353. For generation of the heatmap, all significantly regulated genes were used. For other analysis, genes with an FDR less than 0.05 with more than a 1.5-fold change were considered DEGs. Genes with normalized count below 50 were removed from the list to ensure the quality of DEGs. Pathway analysis was performed using the GSEA program available from the Broad Institute. For qRT-PCR analysis, 500–1,000 ng of RNA was used as a template for cDNA synthesis. We performed qRT-PCR using TaqMan primers purchased from Thermo Fisher Scientific. The resulting data were analyzed using the comparative cycle threshold method to calculate relative RNA quantities (94).

Flow cytometry. For surface protein detection, cells were incubated with Fe Block (Bio X Cell, 2.4G2) for 15 minutes and washed, followed by incubation with viability dye and the indicated Abs directed against cell surface proteins. CM-H2DCFDA, a general oxidative stress indicator, was used to detect total ROS production (18, 56). Cells were incubated with 1 μM CM-H2DCFDA (Thermo Fisher Scientific, C6827) at 37°C for 30 minutes, followed by staining of surface proteins as described above. To detect NOX2-mediated superoxide production, cells were incubated with DHE (Thermo Fisher Scientific, D11347) on ice for 30 minutes, and surface staining was performed simultaneously (97). Fluorescence levels were analyzed by flow cytometry within 6 hours of staining without fixation. For intracellular cytokine staining, cells were stimulated with PMA (25 ng/ml) and ionomycin (1 μg/ml) in the presence of GolgiStop (BD Biosciences) for 4 hours and were permeabilized using the Foxp3 Staining Buffer Kit.
(eBioscience) as previously described (98). For MOG tetramer staining, cells were stained with tetramer at 37°C for 60 minutes (99).

To analyze levels of p-STAT3, cells were stimulated with various cytokines for the indicated times, then fixed with BD Phosflow Lyse/Fix Buffer (BD Biosciences, 558049) immediately after stimulation at 37°C for 10 minutes. Cells were then permeabilized with prechilled BD Phosflow Perm Buffer III (BD Biosciences, 558050) on ice for 30 minutes, followed by staining for p-STAT3 for 1 hour. Stained cells were analyzed by flow cytometry immediately after staining.

For analysis of cells from the in vivo EAE experiments, mice were sacrificed and whole-body perfusion was performed. Mononuclear cells were isolated from the cerebellum using a 30%:70% Percoll (GE Healthcare, 17089101) gradient. Cell phenotypes were determined based on surface and intracellular staining patterns analyzed by flow cytometry as previously described (31, 45). All flow cytometry data were analyzed using FlowJo software (Tree Star Inc.).

**Luminol assay.** Bone marrow neutrophils were incubated with G-CSF (10 ng/ml) for 12 hours, transferred to 96-well plates (2–5 × 10⁵ cells per well), and washed with HBSS. Neutrophils were incubated with PMA (MilliporeSigma, P1585) (10 ng/ml), the cytokine of interest, luminol (MilliporeSigma, 123072) (200 nM), and HRP (MilliporeSigma, P8375) (1.6 units/ml). Luminescence was measured immediately thereafter and every 2 minutes for 60 minutes (100).

**Statistics.** Significant differences between 2 groups were analyzed by Student’s *t* test distribution. One-way ANOVA was used to compare differences between more than 2 samples, and the Mann-Whitney rank-sum test was used for EAE scores. *P* values less than 0.05 were considered statistically significant. All error bars represent ± SEM.

**Study approval.** All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of UAB.

**Author contributions**

ZY, HQ, and ENB designed and analyzed the experiments. ZY, WY, SAG, KSL, LP, HW, and FC performed the experiments. ZY, HQ, and ENB wrote the manuscript. JSD helped design and interpret experiments related to ROS detection. ASW and WC assisted with RNA-Seq data analysis.

**Acknowledgments**

This work was supported by NIH grants R01NS057563 (to ENB), R01AI061061 (to ASW), and R01HL128502 (to JSD) and National Multiple Sclerosis Society grant RG-1606-24794 (to HQ). The Comprehensive Flow Cytometry Core at UAB is supported by NIH grants P30 AR048311 and P30 AI27667. We thank Hubert Tse (UAB) and lab members for their assistance with the luminol assay. We thank Laurie Harrington for the reagents and assistance with tetramer staining.

Address correspondence to: Hongwei Qin, Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, 1918 University Blvd., MCLM 390, Birmingham, Alabama 35294, USA. Phone: 205.934.2573; Email: hqin@uab.edu. Or to: Etty (Tika) Benveniste, Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, 510 20th Street South, 1220 Faculty Office Tower, Birmingham, Alabama 35294, USA. Phone: 205.934.7667; Email: tika@uab.edu.

---


